The Centers for Medicare & Medicaid Services’ (CMS’) final rule advances policies to promote the efficient operation of the Medicaid Drug Rebate Program (MDRP).
Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program Final Rule
Newsroom Homepage
Listing of Newsroom articles
CMS Round Up
CMS Roundup (Mar. 10, 2023)
Today, the Centers for Medicare & Medicaid Services (CMS) is providing an at-a-glance summary of news from around the agency: CMS Releases Guidance for the End of the COVID-19 Public Health Emergency on May 11 — Information on What You Need to Know February 27: CMS is preparing the public for the Read more about CMS Roundup (Mar. 10, 2023)
Press Releases
Readout: Administrator Brooks-LaSure and CMS Leadership Meet with Health Insurance Plans and Associations on Access to and Delivery of Care
On Thursday, March 2, 2023, the Centers for Medicare & Medicaid Services Administrator Chiquita Brooks-LaSure and CMS leadership met with senior leadership of health insurance plans and associations. CMS was pleased to welcome Department of Health and Human Services Secretary Xavier Becerra to open Read more about Readout: Administrator Brooks-LaSure and CMS Leadership Meet with Health Insurance Plans and Associations on Access to and Delivery of Care
Fact Sheets
CMS Waivers, Flexibilities, and the Transition Forward from the COVID-19 Public Health Emergency
What Do I Need to Know? Read more about CMS Waivers, Flexibilities, and the Transition Forward from the COVID-19 Public Health Emergency
CMS Round Up
CMS Roundup (Feb. 24, 2023)
Today, the Centers for Medicare & Medicaid Services (CMS) is providing an at-a-glance summary of news from around the agency: Health Affairs Publishes CMS Analysis that Shows Substantial Progress of Hospital Price Transparency Practices February 14: CMS is making sure hospitals are moving in the Read more about CMS Roundup (Feb. 24, 2023)
Press Releases
CMS STATEMENT: Response to Alzheimer’s Association’s Request to Reconsider the Final National Coverage Determination
Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease Read more about CMS STATEMENT: Response to Alzheimer’s Association’s Request to Reconsider the Final National Coverage Determination
Press Releases